Understanding Clinical Trial Endpoints: What Biotech Investors Need to Know
Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-08. Published by ClinicalInvestor. Educational guide only. Read the editorial policy and disclosures.
When a biotech company announces clinical trial results, the first thing every investor should ask is: did the trial hit its primary endpoint? But understanding what that means requires more than just checking whether a p-value is below 0.05. Endpoints are the specific measurements used to determine whether a drug works. Choosing the right endpoint can make or break a drug's path to approval, and understanding endpoints helps investors evaluate whether positive results are truly meaningful or statistically significant but clinically irrelevant.
What Are Clinical Trial Endpoints?
Key takeaway
The primary endpoint is the single most important measurement in any clinical trial and the basis for FDA approval decisions.
Primary vs. Secondary Endpoints
Key takeaway
Always check the primary endpoint first. Secondary endpoints are supporting evidence, not a substitute for a primary endpoint miss.
Clinical Endpoints vs. Surrogate Endpoints
Key takeaway
Surrogate endpoints offer a faster path to approval but carry additional risk since clinical benefit must still be confirmed.
Common Endpoints in Oncology
Key takeaway
Overall survival is the gold standard in oncology. PFS is commonly used but watch for OS data to confirm the benefit is real.
Common Endpoints Outside Oncology
Key takeaway
Every disease area has standard endpoints. Compare results against historical benchmarks and competitor data using the same endpoints.
Statistical Significance vs. Clinical Meaningfulness
Key takeaway
A low p-value is necessary but not sufficient. Always evaluate whether the magnitude of the treatment effect is clinically meaningful.
Composite Endpoints and How to Evaluate Them
Key takeaway
When a trial uses a composite endpoint, always check which individual components are driving the result.
How Endpoint Choice Affects Stock Price
Key takeaway
Endpoint selection directly impacts the investment timeline and the magnitude of potential stock moves on data readouts.
Key terms
Primary endpoint
The single outcome a trial is designed and powered to test. Regulators judge success mainly on it, and the statistical plan fixes it before the trial starts, so a company cannot pick a better-looking measure afterwards.
Secondary endpoint
Additional outcomes measured in the same trial. They support the primary result and can shape a drug label, but a trial that misses its primary endpoint is not usually rescued by positive secondary endpoints.
Surrogate endpoint
A measurement, such as tumour shrinkage, blood pressure or a lab value, used in place of a clinical outcome because it changes sooner. It is only as useful as its proven link to how patients actually feel, function or survive.
Overall survival (OS)
The time from randomisation until death from any cause. It is the hardest endpoint to argue with in oncology, but it takes the longest to measure and can be diluted when patients switch to other treatments.
Progression-free survival (PFS)
The time from randomisation until the disease worsens or the patient dies. It reads out sooner than overall survival and is common in cancer trials, but a PFS benefit does not always translate into longer life.
Hazard ratio
A comparison of how quickly events such as progression or death occur in the treatment arm versus the control arm. A hazard ratio of 0.70 means a 30% lower rate of events over the period studied.
Composite endpoint
An endpoint that counts any of several events, for example heart attack, stroke or cardiovascular death. It increases the number of events, but a result can be driven mostly by the least serious component.
Next steps
Find the primary endpoint on the trial's ClinicalTrials.gov record before reading the press release, so you know what the company had to show.
Check whether the primary endpoint is a surrogate or a clinical outcome, and whether regulators have accepted that surrogate in this disease before.
Compare the reported effect size with the standard of care, not only with placebo.
Read the safety data with the efficacy data; a modest benefit with real toxicity rarely becomes a commercial success.
Put this guide to work
Use these free ClinicalInvestor tools to apply what you just learned.
PDUFA calendar →
FDA decision dates traced to the filing that states each one.
Biotech Catalyst Calendar →
PDUFA dates, Phase 3 readouts, AdComs, and conferences. Free.
Trial Translator →
Paste any ClinicalTrials.gov ID and get a plain-English AI breakdown.
Biotech Screener →
Filter published biotech profiles by area, phase, market cap, and runway.
Company Profiles →
Pipelines, bull and bear cases, and next expected data for every covered biotech.
Keep learning
Sponsored
Deepen your biotech knowledge with Seeking Alpha PremiumAffiliate link — we may earn a commission at no cost to you